NasdaqGM:EOLS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Evolus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EOLS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: EOLS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-0.8%

EOLS

2.9%

US Pharmaceuticals

0.7%

US Market


1 Year Return

-70.6%

EOLS

7.0%

US Pharmaceuticals

22.2%

US Market

Return vs Industry: EOLS underperformed the US Pharmaceuticals industry which returned 7.4% over the past year.

Return vs Market: EOLS underperformed the US Market which returned 22.7% over the past year.


Shareholder returns

EOLSIndustryMarket
7 Day-0.8%2.9%0.7%
30 Day23.9%7.3%11.8%
90 Day0.3%2.1%8.6%
1 Year-70.6%-70.6%9.7%7.0%25.0%22.2%
3 Yearn/a28.6%19.1%49.4%39.5%
5 Yearn/a41.4%25.1%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Evolus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evolus undervalued compared to its fair value and its price relative to the market?

3.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EOLS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EOLS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EOLS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: EOLS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EOLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EOLS's PB Ratio (3.6x) is in line with the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Evolus forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

71.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EOLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: EOLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EOLS's is expected to become profitable in the next 3 years.

Revenue vs Market: EOLS's revenue (35.9% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: EOLS's revenue (35.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EOLS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evolus performed over the past 5 years?

-43.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EOLS is currently unprofitable.

Growing Profit Margin: EOLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EOLS is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.

Accelerating Growth: Unable to compare EOLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EOLS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: EOLS has a negative Return on Equity (-190.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Evolus's financial position?


Financial Position Analysis

Short Term Liabilities: EOLS's short term assets ($132.4M) exceed its short term liabilities ($12.7M).

Long Term Liabilities: EOLS's short term assets ($132.4M) do not cover its long term liabilities ($168.0M).


Debt to Equity History and Analysis

Debt Level: EOLS's debt to equity ratio (325.3%) is considered high.

Reducing Debt: Insufficient data to determine if EOLS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EOLS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EOLS has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 47.4% each year.


Next Steps

Dividend

What is Evolus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EOLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EOLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EOLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EOLS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EOLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

David Moatazedi (42 yo)

2.58yrs

Tenure

US$2,278,813

Compensation

Mr. David Moatazedi has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Moatazedi served as Senior Vice President of Medical Aesthetics at Alle...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD2.28M) is above average for companies of similar size in the US market ($USD561.50K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
David Moatazedi
President2.58yrsUS$2.28mno data
Lauren Silvernail
CFO & Executive VP of Corporate Development2.58yrsUS$1.02m0.014%
$ 18.2k
Rui Avelar
Chief Medical Officer and Head of Research & Development6.92yrsUS$1.84m0.21%
$ 264.1k
Alejandro Sabad
Vice President of Operations2.17yrsno datano data
Ashwin Agarwal
Vice President of Finance2.25yrsno datano data
Jeffrey Plumer
General Counselno datano datano data
Crystal Muilenburg
Vice President of Corporate Communications & Public Relations1.83yrsno datano data
Kurt Knab
Vice President of Sales2.17yrsno datano data
Dianne Whitfield
Vice President of Human Resources0.92yrno datano data
Michael Jafar
Chief Commercial Officer0.083yrUS$3.93m0.11%
$ 141.7k

2.2yrs

Average Tenure

50yo

Average Age

Experienced Management: EOLS's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Moatazedi
President2.58yrsUS$2.28mno data
Peter Farrell
Independent Director1.42yrsUS$248.47k0%
$ 0
David Gill
Independent Director2.83yrsUS$201.70k0.015%
$ 18.7k
Simone Blank
Director2.92yrsUS$185.70k0.000080%
$ 100.7
Robert Hayman
Independent Director2.92yrsUS$190.70k0%
$ 0
Vikram Malik
Chairman of the Board2.92yrsUS$221.70k3.9%
$ 4.9m
Karah Parschauer
Independent Director1.42yrsUS$248.47k0%
$ 0

2.8yrs

Average Tenure

57yo

Average Age

Experienced Board: EOLS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Evolus, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evolus, Inc.
  • Ticker: EOLS
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$125.885m
  • Shares outstanding: 33.75m
  • Website: https://www.evolus.com

Number of Employees


Location

  • Evolus, Inc.
  • 520 Newport Center Drive
  • Suite 1200
  • Newport Beach
  • California
  • 92660
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EOLSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2018
EVLDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2018
0K16LSE (London Stock Exchange)YesCommon StockGBUSDFeb 2018

Biography

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum to...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:46
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.